FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
FDA lifted clinical hold on VTVT's cadisegliatin program for Type 1 Diabetes. CATT1 Phase 3 trial duration will shorten from 12 to 6 months. Cadisegliatin shows promise as first oral therapy adjunct to insulin. VTVT stock rose 66.70% following the FDA's announcement.
View signal analysis